On January 15, 2024, Chief Commercial Officer James Wilbur and 10x Genomics, Inc. (the ?Company?) entered into a Transition and Separation Agreement (the ?Agreement?) pursuant to which Dr. Wilbur will depart the Company on February 1, 2024. Dr. Wilbur's departure is not due to any disagreement with the Company?s management team, operations, financial statements, policies or procedures.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
19.96 USD | +0.96% |
|
-6.51% | -64.33% |
Jun. 03 | Jefferies Initiates 10x Genomics at Hold Rating With $24 Price Target | MT |
May. 29 | 10x Genomics, Inc. Launches 5,000-Plex Gene Panel for Xenium | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-64.33% | 2.37B | |
-10.93% | 11.41B | |
-11.84% | 7.53B | |
+31.42% | 5.62B | |
+4.38% | 5.54B | |
-17.33% | 3.82B | |
+7.01% | 2.6B | |
-10.17% | 2.26B | |
+24.35% | 2.16B | |
-12.83% | 1.71B |
- Stock Market
- Equities
- TXG Stock
- News 10x Genomics, Inc.
- James Wilbur to Depart from 10X Genomics, Inc. as Chief Commercial Officer, Effective from February 1, 2024